Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Daniel E. Fürst, Edward Keystone, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2011 · 692 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

G. M. Bartelds, Carla A. Wijbrandts, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2007 · 567 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 520 citations

Medicine, Clinical Sciences, Pharmacotherapy +12

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

Marijn Vis, Willem F. Lems, Alexandre E. Voskuyl et al. · Arthritis & Rheumatism · 2006 · 469 citations

Medicine, Clinical Sciences, Internal Medicine +17

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

Kimme L Hyrich, Mark Lunt, Kath Watson et al. · Arthritis & Rheumatism · 2006 · 403 citations

Medicine, Pharmacology, Pharmacotherapy +13